March 06, 2015 1:23 AM ET


Company Overview of Relypsa, Inc.

Company Overview

Relypsa, Inc., a pharmaceutical company, focuses on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular, and metabolic diseases in the United States. The company’s principal product candidate includes Patiromer, a non-absorbed potassium binder that completed Phase 3 clinical trial for the treatment of hyperkalemia. It also offers RLY6002, a pre-clinical product candidate that evaluates as an adjunct to diet and exercise to enhance glycemic control in adults with type 2 diabetes mellitus. The company was founded in 2007 and is headquartered in Redwood City, California.

100 Cardinal Way

Redwood City, CA 94063

United States

Founded in 2007

99 Employees



Key Executives for Relypsa, Inc.

Chief Executive Officer, President and Director
Age: 49
Total Annual Compensation: $287.3K
Total Annual Compensation: $172.5K
Chief Medical Officer and Senior Vice President
Age: 43
Total Annual Compensation: $321.9K
Senior Vice President of Pharmaceutical Development & Regulatory Affairs
Age: 61
Total Annual Compensation: $304.0K
Compensation as of Fiscal Year 2013.

Relypsa, Inc. Key Developments

Relypsa, Inc. Appoints Helen Torley as Director

Relypsa, Inc. announced that Helen Torley, M.B. Ch.B., M.R.C.P., has been appointed to the company's board of directors, bringing the number of directors to nine. Dr. Torley, current president and chief executive officer of Halozyme Therapeutics, brings to the board significant industry experience and deep knowledge and expertise in development and commercialization of biopharmaceutical products, including several recent successful product launches. Prior to joining Halozyme in January 2014, Dr. Torley served as executive vice president and chief commercial officer for Onyx harmaceuticals, where she oversaw the collaboration with Bayer on Nexavar and Stivarga and the U.S. launch of Kyprolis. From 2003 to 2011, she held management positions at Amgen, most recently as vice president and general manager of the U.S. Nephrology Business Unit and the U.S. Bone Health Business Unit. Previously, she held various senior management positions at Bristol-Myers Squibb, including regional vice president of Cardiovascular and Metabolic Sales and head of Cardiovascular Global Marketing. She began her career at Sandoz/Novartis, where she ultimately served as vice president of Medical Affairs, developing and conducting post-marketing clinical studies across all therapeutic areas.

Relypsa, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-03-2015 08:40 AM

Relypsa, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-03-2015 08:40 AM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States. Speakers: John A. Orwin, Chief Executive Officer, President and Director.

Relypsa, Inc. - Analyst/Investor Day

Relypsa, Inc. - Analyst/Investor Day

Similar Private Companies By Industry

Company Name Region
Antipodean Pharmaceuticals, Inc United States
MPM Medical, Inc. United States
Bioponic Phytoceuticals, Inc. United States
ClinCyte LLC United States
DxCon, Inc. United States

Recent Private Companies Transactions

Private Placement
May 30, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Relypsa, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at